These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38134554)

  • 1. Changes of FGF23 and hearing in chronic renal failure and their correlation analysis.
    Li J; Nie J; Zhou Z; Guo M; Yang Q; Yuan D; Huang J; Li R; Li Q
    Cytokine; 2024 Feb; 174():156478. PubMed ID: 38134554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N; Miyata S; Abe M; Kobayashi N; Wakita S; Yamashita T; Wada M
    Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats.
    Kusano K; Saito H; Segawa H; Fukushima N; Miyamoto K
    J Nutr Sci Vitaminol (Tokyo); 2009 Apr; 55(2):99-105. PubMed ID: 19436134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.
    Lavi-Moshayoff V; Wasserman G; Meir T; Silver J; Naveh-Many T
    Am J Physiol Renal Physiol; 2010 Oct; 299(4):F882-9. PubMed ID: 20685823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fortified phosphorus‑lowering treatment through administration of lanthanum protects against vascular calcification via regulation of FGF23 in chronic kidney disease.
    Jiang J; Li Y; Zheng D; Wang Z; Zhou H; Liu G
    Int J Mol Med; 2020 Nov; 46(5):1783-1793. PubMed ID: 32901861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
    Phelps KR; Mason DL
    Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model.
    Sugiura H; Matsushita A; Futaya M; Teraoka A; Akiyama KI; Usui N; Nagano N; Nitta K; Tsuchiya K
    PLoS One; 2018; 13(3):e0191706. PubMed ID: 29518087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure.
    Martínez-Arias L; Panizo-García S; Martín-Vírgala J; Martín-Carro B; Fernández-Villabrille S; Avello-Llano N; Miguel-Fernández D; Ruíz Torres MP; Cannata-Andía JB; Carrillo-López N; Naves-Díaz M
    Nefrologia (Engl Ed); 2021; 41(6):640-651. PubMed ID: 36165154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.
    Saji F; Shigematsu T; Sakaguchi T; Ohya M; Orita H; Maeda Y; Ooura M; Mima T; Negi S
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1212-7. PubMed ID: 20739393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate homeostasis, parathyroid hormone, and fibroblast growth factor 23 in stages 3 and 4 chronic kidney disease.
    Phelps KR; Mason DL; Stote KS
    Clin Nephrol; 2016 May; 85(5):251-61. PubMed ID: 26951967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT assessment of bone remodeling in the otic capsule in chronic renal failure: association with hearing loss.
    Erkoç MF; Bulut S; İmamoğlu H; Gümüş C; Kayataş M
    AJR Am J Roentgenol; 2013 Feb; 200(2):396-9. PubMed ID: 23345363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
    Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
    Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Masutani K; Ooboshi H; Kitazono T
    Ther Apher Dial; 2015 Feb; 19(1):73-80. PubMed ID: 25195562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The correlation between fibroblast growth factor-23 and ESRD patients with hearing impairment.
    Nie J; Li Q; Guo M; Li J; Yang J; Chang Q; Cai Y
    PeerJ; 2021; 9():e12295. PubMed ID: 34721981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum sclerostin in acute kidney injury patients.
    Fayed A; Abdulazim DO; Amin M; Elhadidy S; Samir HH; Salem MM; Abd ElAzim IM; El Hawary KES; Sharaf El Din UA;
    Nefrologia (Engl Ed); 2022; 42(1):50-55. PubMed ID: 36153899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quercetin Treatment Improves Renal Function and Protects the Kidney in a Rat Model of Adenine-Induced Chronic Kidney Disease.
    Yang H; Song Y; Liang YN; Li R
    Med Sci Monit; 2018 Jul; 24():4760-4766. PubMed ID: 29987270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation study of FGF23/D-serine in maintenance hemodialysis patients with combined hearing impairment.
    Yuan D; Li J; Guo M; Yang Q; Huang J; Nie J; Li R; Li Q
    PLoS One; 2023; 18(1):e0280378. PubMed ID: 36649363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.